Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark

Cancer Genetics and Cytogenetics

Volumn 174, Issue 2, 2007, Pages 89-99

  Christensen, Jacob H ^a   Abildgaard, Niels ^a   Plesner, Torben ^b   Nibe, Anne ^a   Nielsen, Ole ^a   Sørensen, Anne G ^a   Kerndrup, Gitte B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME ARM; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DENMARK; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GAMMOPATHY; GENE TRANSLOCATION; HUMAN; INTERPHASE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TETRAPLOIDY; TRIPLOIDY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 4; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; PLASMA CELLS; TIME FACTORS; TRANSLOCATION, GENETIC;

EID: 34247157300     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.11.015     Document Type: Article

References (39)

1. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., Fonseca R., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.E., Therneau T.M., and Greipp P.R. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 (2003) 21-33
2. Hjorth M., Westin J., Dahl I.M.S., Gimsing P., Hippe E., Holmberg E., Lamvik J., Nielsen J.L., Lofvenberg E., Palva I.P., Rodjer S., Talstad I., Turesson I., Wisloff F., Zador G., and The Nordic Myeloma Study Group. Interferon-α 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med 124 (1996) 212-222
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
4. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R., and du Myélome I.F. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
5. Lenhoff S., Hjorth M., Holmberg E., Turesson I., Westin J., Nielsen J.L., Wisloff F., Brinch L., Carlson K., Carlsson M., Dahl I.M., Gimsing P., Hippe E., Johnsen H., Lamvik J., Lofvenberg E., Nesthus I., Rodjer S., and Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95 (2000) 7-11
6. Depil S., Leleu X., Micol J.B., Berthon C., Lai J.L., Bauters F., Quesnel B., and Facon T. Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk Lymphoma 45 (2004) 2481-2484
7. Dewald G.W., Therneau T., Larson D., Lee Y.K., Fink S., Smoley S., Paternoster S., Adeyinka A., Ketterling R., Van Dyke D.L., Fonseca R., and Kyle R. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106 (2005) 3553-3558
8. Fonseca R., Hoyer J.D., Aguayo P., Jalal S.M., Ahmann G.J., Rajkumar S.V., Witzig T.E., Lacy M.Q., Dispenzieri A., Gertz M.A., Kyle R.A., and Greipp P.R. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma 35 (1999) 599-605
9. García-Sanz R., González-Fraile M.I., Mateo G., Hernández J.M., López-Berges M.C., de las Heras N., Fernández-Calvo J., Ortega F., Portero J.A., Bárez A., Galende J., Orfão A., and San Miguel J.F. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 112 (2004) 884-889
10. Hoechtlen-Vollmar W., Menzel G., Bartl R., Lamerz R., Wick M., and Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 109 (2000) 30-38
11. Konigsberg R., Zojer N., Ackermann J., Kromer E., Kittler H., Fritz E., Kaufmann H., Nosslinger T., Riedl L., Gisslinger H., Jager U., Simonitsch I., Heinz R., Ludwig H., Huber H., and Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18 (2000) 804-812
12. Lai J.L., Zandecki M., Mary J.Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Jouet J.P., Bauters F., and Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85 (1995) 2490-2497
13. Rajkumar S., Fonseca R., Lacy M., Witzig T., Lust J., Greipp P., Therneau T., Kyle R., Litzow M., and Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 24 (1999) 497-503
14. Zojer N., Konigsberg R., Ackermann J., Fritz E., Dallinger S., Kromer E., Kaufmann H., Riedl L., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H., and Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 (2000) 1925-1930
15. Gutiérrez N.C., García J.L., Hernández J.M., Lumbreras E., Castellanos M., Rasillo A., Mateo G., Hernández J.M., Pérez S., Orfao A., and San Miguel J.F. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 104 (2004) 2661-2666
16. Harousseau J.L., Shaughnessy Jr. J., and Richardson P. Multiple myeloma. Hematology Am Soc Hematol Educ Program (2004) 237-256
17. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevieve F., Zandecki M., Lai J.L., Leleu X., Jouet J.P., Bauters F., Harousseau J.L., Bataille R., and Mary J.Y. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
18. Shaughnessy J., Tian E., Sawyer J., Bumm K., Landes R., Badros A., Morris C., Tricot G., Epstein J., and Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96 (2000) 1505-1511
19. Chang H., Qi C., Yi Q.L., Reece D., and Stewart A.K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
20. Smadja N.V., Bastard C., Brigaudeau C., Leroux D., and Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
21. Moreau P., Facon T., Leleu X., Morineau N., Huyghe P., Harousseau J.L., Bataille R., and Avet-Loiseau H. Intergroupe Francophone du Myélome. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100 (2002) 1579-1583
22. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139-149
23. L'Hôte C.G., and Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304 (2005) 417-431
24. Grand E.K., Chase A.J., Heath C., Rahemtulla A., and Cross N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18 (2004) 962-966
25. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., Reece D., Heise C., and Stewart A.K. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 (2005) 2941-2948
26. Trudel S., Stewart A.K., Rom E., Wei E., Li Z.H., Kotzer S., Chumakov I., Singer Y., Chang H., Liang S.B., and Yayon A. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 (2006) 4039-4046
27. Pedersen R.K., Kerndrup G.B., Sorensen A.G., Mourits-Andersen T., Gram-Hansen P., Pulczynski S., and Schmidt K.G. Cytogenetic aberrations in adult acute lymphocytic leukemia: optimal technique may influence the results. Cancer Genet Cytogenet 128 (2001) 7-10
28. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., Kuehl W.M., Hernandez J.M., Minvielle S., Pilarski L.M., Shaughnessy Jr. J.D., Stewart A.K., and Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
29. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., Minvielle S., and Bataille R. Intergroupe Francophone du Myélome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
30. Garcia-Marco J.A., Caldas C., Price C.M., Wiedemann L.M., Ashworth A., and Catovsky D. Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia. Blood 88 (1996) 1568-1575
31. Fonseca R., Oken M.M., Harrington D., Bailey R.J., Van Wier S.A., Henderson K.J., Kay N.E., Van Ness B., Greipp P.R., and Dewald G.W. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15 (2001) 981-986
32. Avet-Loiseau H., Li J.Y., Godon C., Morineau N., Daviet A., Harousseau J.L., Facon T., and Bataille R. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 106 (1999) 717-719
33. Drach J., Ackermann J., Fritz E., Kromer E., Schuster R., Gisslinger H., DeSantis M., Zojer N., Fiegl M., Roka S., Schuster J., Heinz R., Ludwig H., and Huber H. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92 (1998) 802-809
34. Fonseca R., Blood E.A., Oken M.M., Kyle R.A., Dewald G.W., Bailey R.J., Van Wier S.A., Henderson K.J., Hoyer J.D., Harrington D., Kay N.E., Van Ness B., and Greipp P.R. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99 (2002) 3735-3741
35. Debes-Marun C.S., Dewald G.W., Bryant S., Picken E., Santana-Davila R., Gonzalez-Paz N., Winkler J.M., Kyle R.A., Gertz M.A., Witzig T.E., Dispenzieri A., Lacy M.Q., Rajkumar S.V., Lust J.A., Greipp P.R., and Fonseca R. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17 (2003) 427-436
36. Wuilleme S., Robillard N., Lode L., Magrangeas F., Beris H., Harousseau J.L., Proffitt J., Minvielle S., and Avet-Loiseau H. Intergroupe Francophone du Myélome. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19 (2005) 275-278
37. Gabrea A., Leif B.P., and Michael K.W. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst) (2006)
38. Calasanz M.J., Cigudosa J.C., Odero M.D., Garcia-Foncillas J., Marin J., Ardanaz M.T., Rocha E., and Gullon A. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 98 (1997) 418-425
39. Fassas A.B., Spencer T., Sawyer J., Zangari M., Lee C.K., Anaissie E., Muwalla F., Morris C., Barlogie B., and Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118 (2002) 1041-1047